Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography

Annals of the Rheumatic Diseases

Volumn 65, Issue 4, 2006, Pages 501-507

  Peake, N J ^b   Foster, H E ^b   Khawaja, K ^c   Cawston, T E ^b   Rowan, A D ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE; GELATINASE A; GELATINASE B; LIPOCALIN;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYNOVIAL FLUID; ZYMOGRAPHY;

ADOLESCENT; ADULT; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; CHILD; CHILD, PRESCHOOL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GELATINASES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PLATELET COUNT; SYNOVIAL FLUID;

EID: 33645116863     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.039032     Document Type: Article

References (34)

1. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39.
2. Murphy G, Knauper V, Atkinson S, Butler G, English W, Mutton M, et al. Matrix metalloproteinases in arthritic disease. Arthritis Res 2002;4(suppl 3):S39-49.
3. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, et al. Matrix metalloproteinases and tissue inhibitors or metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000;59:455-61.
4. Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691-7.
5. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci USA 1990;87:364-8.
6. Coughlan AR, Robertson DH, Bennett D, May C, Beynon RJ, Carter SD. Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis. Vet Rec 1998;143:219-23.
7. Hu LT, Eskildsen MA, Masgala C, Steere A C, Arner EC, Pratta MA, et al. Host metalloproteinases in Lyme arthritis. Arthritis Rheum 2001;44:1401-10.
8. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995;270:5872-6.
9. Tam EM, Moore TR, Butler GS, Overall CM. Characterization of the distinct collagen binding, helicase and cleavage mechanisms of matrix metalioproteinase 2 and 14 (gelatinase A and MT1-MMP): the differential roles of the MMP hemopexin c domains and the MMP-2 fibronectin type II modules in collagen triple helicase actvities. J Biol Chem 2004;279:43336-44.
10. Makowski GS, Ramsby ML. Zymographic analysis of latent and activated forms of matrix metalloproteinase-2 and -9 in synovial fluid: correlation to polymorphonuclear leukocyte infiltration and in response to infection. Clin Chim Acta 2003;329:77-81.
11. Olson MW, Bernardo MM, Pietila M, Gervasi DC, Tom M, Kotra LP, et al. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem 2000;275:2661-8.
12. Tschesche H, Zolzer V, Triebel S, Bartsch S. The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem 2001;268:1918-28.
13. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
14. Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003;48:767-75.
15. Oen K, Reed M, Malleson PN, Cabral DA, Petty RE, Rosenberg AM, et al. Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J Rheumatol 2003;30:832-40.
16. Bayliss MT, Ali SY. Age-related changes in the composition and structure of human articular-cartilage proteoglycans. Biochem J 1978;176:683-93.
17. Dudhia J, Davidson CM, Wells TM, Vynios DH, Hardingham TE, Bayliss MT. Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage. Biochem J 1996;313:933-40.
18. Gattomo M, Vignola S, Falcini F, Sabatini F, Buoncompagni A, Simonini G, et al. Serum and synovial fluid concentrations of matrix metalloproteinases 3 and its tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol 2002;29:826-31.
19. Hasty KA, Reife RA, Kang AH, Stuart JM. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum 1990;33:388-97.
20. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes Biochem J 1987;248:265-8.
21. Knauper V, Wilhelm SM, Seperack PK, DeClerck YA, Langlev KE, Osthues A, et al. Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J 1993;295:581-6.
22. Matsuyama T. Tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis. Pediatr Int 1999;41:239-45.
23. Dreier R, Grassei S, Fuchs S, Schaumburger J, Bruckner P. Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade. Exp Cell Res 2004;297:303-12.
24. Unemori EN, Hibbs MS, Amento EP. Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines. J Clin Invest 1991;88:1656-62.
25. Jin G, Sah RL, Li YS, Lotz M, Shw JY, Chien S. Biomechanical regulation of matrix metalloproteinase-9 in cultured chondrocytes. J Orthop Res 2000;18:899-908.
26. Marini S, Fasciglione GF, Monteleone G, Maiotti M, Tarantino U, Coletta M. A correlation between knee cartilage degradation observed by arthroscopy and synovial proteinases activities. Clin Biochem 2003;36:295-304.
27. Jubb RW, Fell HB. The breakdown of collagen by chondrocytes. J Pathol 1980;130:159-67.
28. Kerkvliet EH, Docherty AJ, Beertsen W, Everts V. Collagen breakdown in soft connective tissue explants is associated with the level of active gelatinase A (MMP-2) but not with collagenase. Matrix Biol 1999;18:373-80.
29. Mannello F, Luchetti F, Canonico B, Papa S. Effect of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin Chem 2003;49:1956-7.
30. Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001;314:241-4.
31. Schmitz JP, Dean DD, Schwartz Z, Cochran DL, Grant GM, Klebe RJ, et al. Chondrocyte cultures express matrix metalloproteinase mRNA and immunoreactive protein; stromelysin-1 and 72 kDa gelatinase are localized in extracellular matrix vesicles. J Cell Biochem 1996;61:375-91.
32. Milner JM, Elliott SF, Cawston TE. Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways. Arthritis Rheum 2001;44:2084-96.
33. Makowski GS, Ramsby ML. Identification and partial characterization of three calcium- and zinc-independent gelatinases constitutively present in human circulation. Biochem Mol Biol Int 1998;46:1043-53.
34. Bigg HF, Rowan AD. The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis. Curr Opin Pharmacol 2001;1:314-20.